Valeo Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Feb '26 Feb 10, 2026	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019
Market Capitalization	0	10	40	54	44	-
Market Cap Growth	-100.00%	-74.23%	-25.13%	21.74%	-	-
Enterprise Value	46	52	64	55	47	-
Last Close Price	0.00	0.10	0.49	0.68	0.69	-
PS Ratio	-	0.27	1.97	4.90	7.85	-
PB Ratio	-	-0.36	-3.07	32.38	19.10	-
P/TBV Ratio	-	-	-	-	67.22	-
EV/Sales Ratio	1.19	1.33	3.13	5.00	8.42	-
Debt / Equity Ratio	-1.12	-1.63	-3.44	3.74	1.06	-45.50
Net Debt / Equity Ratio	-1.01	-1.44	-2.18	2.74	0.14	-30.27
Net Debt / EBITDA Ratio	-4.51	-4.47	-2.42	-0.51	-0.11	-0.18
Net Debt / FCF Ratio	-15.81	-3.60	-1.35	-0.43	-0.08	-0.29
Asset Turnover	1.37	1.08	0.70	0.85	0.89	1.43
Inventory Turnover	4.22	3.89	2.18	2.20	8.45	15.78
Quick Ratio	0.17	0.69	1.82	0.25	0.95	0.21
Current Ratio	0.27	1.25	2.64	0.81	1.26	0.37
Return on Equity (ROE)	-	-	-	-555.76%	-312.50%	-
Return on Assets (ROA)	-26.07%	-19.18%	-27.03%	-44.47%	-31.66%	-50.82%
Return on Capital Employed (ROCE)	43.00%	-72.90%	-39.90%	-199.80%	-63.50%	-281.00%
Earnings Yield	-23487830.30%	-193.51%	-47.02%	-21.41%	-8.12%	-
FCF Yield	-2941097.98%	-112.54%	-52.71%	-19.88%	-9.14%	-
Buyback Yield / Dilution	-5.42%	-6.50%	-15.63%	-20.76%	-16.78%	-39.09%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.